Your browser doesn't support javascript.
loading
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.
Janas, Maja M; Harbison, Carole E; Perry, Victoria K; Carito, Brenda; Sutherland, Jessica E; Vaishnaw, Akshay K; Keirstead, Natalie D; Warner, Garvin.
Affiliation
  • Janas MM; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Harbison CE; Authors contributed equally to this work.
  • Perry VK; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Carito B; Authors contributed equally to this work.
  • Sutherland JE; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Vaishnaw AK; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Keirstead ND; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Warner G; 1 Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Toxicol Pathol ; 46(7): 735-745, 2018 10.
Article in En | MEDLINE | ID: mdl-30139307
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acetylgalactosamine / Chromosome Aberrations / RNA, Small Interfering / Liver Limits: Animals Language: En Journal: Toxicol Pathol Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acetylgalactosamine / Chromosome Aberrations / RNA, Small Interfering / Liver Limits: Animals Language: En Journal: Toxicol Pathol Year: 2018 Document type: Article Affiliation country: Country of publication: